Market Insights - Industry Research Report

BCG Vaccine Market

Report on BCG Vaccine Market: Size, Share, and Growth – Covering By Type (Subunit Vaccines, Inactivated, Live Attenuated, mRNA vaccines, Others), By Disease Indication (Viral Diseases, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines), By Age Group (Adults, Pediatrics), By Application (Tuberculosis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy) Segments, and Regional Analysis – Providing a Global and Regional Industry Overview, Market Intelligence, Premium Insights, Comprehensive Analysis, Historical Data, and Forecasts for the Period 2024-2032

The Global BCG Vaccine Market size is estimated at USD 104.84 million in 2023 and is expected to reach USD 175.63 million by 2032, growing at a CAGR of 5.9% during the forecast period (2024-2032).

This surge is fueled by factors such as the prevalence of tuberculosis, advancements in vaccine research and development, and governmental initiatives promoting vaccination campaigns. This article explores the market dynamics, the impact of the COVID-19 pandemic, age group differentials, applications, distribution channels, regional insights, and the competitive landscape within the BCG vaccine market.

BCG Vaccine Market Overview
Factors Driving Growth
  1. Prevalence of Tuberculosis: Tuberculosis, ranking 13th in global mortality, is a key driver, with an anticipated 10.6 million cases in 2021.
  2. Technological Advancements: Advances in vaccine research and development contribute to the market’s upward trajectory.
  3. Government Initiatives: Increased governmental initiatives globally to combat tuberculosis through vaccination campaigns.
Impact of COVID-19

The initial impact of the COVID-19 pandemic resulted in a substantial decline in demand for the BCG vaccine due to strict lockdowns and reduced healthcare facility visits. Manufacturing prioritization of COVID-19 vaccines also led to shortages in BCG vaccines. However, the market is expected to rebound as the pandemic is gradually brought under control.

BCG Vaccine Market

Age Group Insights

  • Pediatrics Leading the Charge

The market is segmented into adults and pediatrics. In 2022, the pediatrics segment dominated, driven by children’s susceptibility to tuberculosis, especially in developing countries. Pediatric tuberculosis accounted for approximately 31% of the global burden, intensifying the demand for pediatric BCG vaccines.

Application Insights

  • Tackling Tuberculosis

The BCG vaccine market is segmented by application into bladder cancer and tuberculosis. The tuberculosis segment held the majority share in 2022 due to the rising global prevalence of tuberculosis. Government initiatives, such as India’s TB Report 2022, emphasize the severity of pediatric tuberculosis, further propelling BCG vaccination rates.

Distribution Channel Insights

  • Retail Pharmacies at the Helm

The distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies. In 2022, retail pharmacies led the market, offering personalized advice and attracting buyers. Their role in managing complicated ailments like tuberculosis and bladder cancer contributes to their market dominance.

Regional Insights

  • Asia Pacific Dominance

Asia Pacific emerged as the dominant region in 2022. Factors contributing to this dominance include the rise in TB cases, increased immunization programs, major players investing in BCG vaccine development, and government funding in healthcare. The vulnerability to tuberculosis due to factors like homelessness and poverty also contributes to the market’s growth in countries like India and China.

Competitive Landscape

Key Players and Strategic Initiatives
  • Major players in the BCG vaccine market include Serum Institute of India Pvt. Ltd., Microgen, Merck & Co., Inc., Japan BCG Laboratory, and AJ Biologics Sdn Bhd. These players engage in strategic initiatives such as product launches, collaborations, mergers, and acquisitions. Notable instances include the WHO’s launch of the “TB Vaccine Accelerator Council” and the Serum Institute of India seeking emergency use authorization for its recombinant BCG vaccine.
Global BCG Vaccine Market Report Segmentation

Type Outlook (Revenue, USD Million, 2018 – 2032)

  1. Subunit Vaccines
    1. Recombinant vaccines
    2. Conjugate Vaccines
    3. Toxoid vaccines
  2. Inactivated
  3. Live Attenuated
  4. mRNA vaccines
  5. Viral vector vaccines

Route Of Administration Outlook (Revenue, USD Million, 2018 – 2032)

  1. Oral
  2. Parenteral
  3. Nasal

Disease Indication Outlook (Revenue, USD Million, 2018 – 2032)

  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. MMR
    4. Rotavirus
    5. Covid-19
    6. Others
  2. Bacterial Vaccines
    1. Meningococcal Diseases
    2. Pneumococcal Diseases
    3. DPT
  3. Cancer Vaccines
  4. Allergy Vaccines

Age Group Outlook (Revenue, USD Million, 2018 – 2032)

  1. Pediatric
  2. Adult

Distribution Channel Outlook (Revenue, USD Million, 2018 – 2032)

  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others

Regional Outlook (Revenue, USD Million, 2018 – 2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • New Zealand
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa (MEA)
    • UAE
    • South Africa
BCG Vaccine Market Report Scope
Report Attribute Details
Market Size Value in 2023 USD 104.84 Million
Revenue Forecast in 2032 USD 175.63 Million
Growth Rate CAGR of 5.9% from 2024 to 2032
Base Year for estimation 2023
Historical Data 2018 – 2023
Forecast Period 2024. – 2032
Report Updated Feb-24
Quantitative Units Revenue in USD million and CAGR from 2024 to 2032
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered Type, Route Of Administration, Disease Indication, Age Group, Distribution Channel, and Region
Regional Scope North America; Europe; Asia Pacific; Latin America; MEA
Country Scope U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key Companies Profiled Serum Institute of India Pvt. Ltd., Microgen, Merck & Co., Inc., Japan BCG Laboratory, AJ Biologics Sdn Bhd, and Others.
Conclusion

As the global BCG vaccine market rides the waves of technological innovation, increasing awareness, and strategic collaborations, it stands resilient against challenges posed by the COVID-19 pandemic. With a focus on pediatric vaccination, addressing tuberculosis, and expanding market avenues, the BCG vaccine market is poised for sustained growth in the coming years.

Frequently Asked Questions

The global BCG Vaccine market was valued at USD 104.84 million in 2023.
Anticipated to exhibit a compound annual growth rate of 5.9% from 2024 to 2032, the global BCG Vaccine market is forecasted to achieve a valuation of USD 175.63 million by 2032.
Key influencers in the BCG Vaccine market landscape include Serum Institute of India Pvt. Ltd., Microgen, Merck & Co., Inc., Japan BCG Laboratory, and AJ Biologics Sdn Bhd and Others.

Share

Get in Touch with Us